Click here to read the fourth edition of the PRISM newsletter.
PRISM project coordinator Prof. Dr. Martien Kas gave a presentation at this year’s ECNP Congress in Paris. The guiding theme was the question on how to get from diagnosis to a deeper understanding of the biological root causes for social withdrawal as a common symptom of many mental disorders. Kas highlighted the PRISM project with its main objective of providing quantitative biological measures to facilitate the discovery and development of new treatments for social and cognitive deficits in Alzheimer’s disease, schizophrenia and depression.
Within the projec t, which is funded by the European Commission’s Innovative Medicines Initiative 2, the Professor of Behavioural Neuroscience at the Groningen Institute of Evolutionary Life Sciences is focused on reaching scientific consensus on study designs by harmonizing both clinical and pre-clinical approaches.
“There is a need to implement homologous clinical and preclinical testing paradigms in order to assess quantitative biological parameters across the diagnostic boundaries”, Kas said. “This will provide preclinical model systems to back-translate human findings and further expand our neurobiological knowledge.”
In his own lab, Kas carries out cross-species genetic analyses of neurobiological substrates for maladaptive behaviors of neuropsychiatric disorders. These are often characterized by inappropriate behavioral responses to environmental cues. A possible approach to compare the responses of subjects with social and cognitive deficits to those of healthy subjects is by visualizing their respective motion patterns in closed environments. Kas illustrated this method during his talk at ECNP 2017.
The annual ECNP Congress is one of Europe’s largest and most renowned scientific meetings for disease-oriented brain research. Attracting between 4,000 and 6,000 neuroscientists, psychiatrists, neurologists and psychologists from around the world, the congress, which celebrated its 30th anniversary in Paris in September 2017, is a major hub for cutting-edge scientific exchange in the field.
WP6 colleagues had productive and lively discussions on the implementation of the pre-clinical studies in the PRISM project.
Martien Kas, PRISM Coordinator: “Great to see the very enthusiastic PRISM team at the start-up meeting of the clinical deep phenotyping study in Amsterdam! We plan to have the first patient in the study towards the end of May 2017.”
Dr. Hugh Marston and Prof. dr. Martien Kas presented the PRISM project at the ECNP Innovation meeting, entitled “New approaches to psychiatric drug development”. At this meeting in Nice, PRISM was perceived as an exemplar project in which a paradigm shift is being introduced paving the road for acceleration of the neuropsychiatric drug discovery process.
Click here to view the meeting programme.